| Careplus Family Medical, Llc | |
|
8914 Us Highway 431 Albertville AL 35950-0157 | |
| (256) 279-7200 | |
| (256) 279-5757 |
| Full Name | Careplus Family Medical, Llc |
|---|---|
| Speciality | Family Medicine |
| Location | 8914 Us Highway 431, Albertville, Alabama |
| Authorized Official Name and Position | Dawn Vaughn (OWNER/ADMINISTRATOR) |
| Authorized Official Contact | 2563104941 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Careplus Family Medical, Llc 8914 Us Highway 431 Albertville AL 35950-0157 Ph: (256) 279-7200 | Careplus Family Medical, Llc 8914 Us Highway 431 Albertville AL 35950-0157 Ph: (256) 279-7200 |
| NPI Number | 1639503055 |
|---|---|
| Provider Enumeration Date | 08/22/2013 |
| Last Update Date | 08/22/2013 |
| Medicare PECOS PAC ID | 9335374255 |
|---|---|
| Medicare Enrollment ID | O20131031001169 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639503055 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | DO645 (Alabama) | Primary |
| 207R00000X | Internal Medicine | 22943 (Alabama) | Secondary |
| Provider Name | Summer M Phelps |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1689890337 PECOS PAC ID: 6608882881 Enrollment ID: I20060224000432 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
| Provider Name | Jonathan C Hood |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1467471003 PECOS PAC ID: 5193734614 Enrollment ID: I20060411000799 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
| Provider Name | Tonya L Moses |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1710038906 PECOS PAC ID: 1254419880 Enrollment ID: I20080423000360 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
| Provider Name | Howard E Mcveigh |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1356404776 PECOS PAC ID: 7719907732 Enrollment ID: I20090702000572 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
| Provider Name | Benjamin S Favis |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1386781664 PECOS PAC ID: 6305989302 Enrollment ID: I20100129000369 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
| Provider Name | Daniel C Burnes |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1487851077 PECOS PAC ID: 6002931623 Enrollment ID: I20100920000130 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
| Provider Name | Sherry K Williams |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386968170 PECOS PAC ID: 0749472801 Enrollment ID: I20101007000426 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
| Provider Name | Amye W Groves |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295030393 PECOS PAC ID: 1254429608 Enrollment ID: I20110307000804 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
| Provider Name | Shanda P Cotney |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255588893 PECOS PAC ID: 2163588088 Enrollment ID: I20110518000535 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
| Provider Name | Melissa Ashley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1497720262 PECOS PAC ID: 7012947492 Enrollment ID: I20111012000571 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
| Provider Name | Messalina C Jordan |
|---|---|
| Provider Type | Practitioner - General Practice |
| Provider Identifiers | NPI Number: 1114218039 PECOS PAC ID: 2860647237 Enrollment ID: I20130311000148 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
| Provider Name | Corey W Gilliland |
|---|---|
| Provider Type | Practitioner - General Practice |
| Provider Identifiers | NPI Number: 1043335136 PECOS PAC ID: 3870494776 Enrollment ID: I20130925000839 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
| Provider Name | Bradley Elliott |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1700267507 PECOS PAC ID: 7315255072 Enrollment ID: I20150929001864 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
| Provider Name | Kim A Driggers |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1407332232 PECOS PAC ID: 5698028413 Enrollment ID: I20181025000040 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
| Provider Name | Chelsea J Lowery |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295219087 PECOS PAC ID: 0840538641 Enrollment ID: I20190220000849 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
| Provider Name | Chasen Uptain |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1942747704 PECOS PAC ID: 7810236064 Enrollment ID: I20190305002432 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
| Provider Name | Stephanie Gwen Rodenberry |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1235725615 PECOS PAC ID: 3072922467 Enrollment ID: I20210517000207 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
| Provider Name | Bethany Nailor |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1013678713 PECOS PAC ID: 6103210802 Enrollment ID: I20220223000312 |
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
News Archive
CongressDaily: "Medicare physician payments, unemployment benefits, aid to states and long-stalled tax breaks were all still in limbo Tuesday with no clear path forward." House Democrats are waiting for the Senate to act on the larger bill before considering a separate "doc fix" bill the Senate passed last week.
We are all aware of the health benefits of "dietary fibre". But what is dietary fibre and how do we metabolise it?
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applications about ACE, a "master" disease gene.
› Verified 8 days ago
Outside The Box Healthcare Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 5730 Us Highway 431, Albertville, AL 35950 Phone: 256-907-9700 Fax: 256-907-9724 | |
New Life Family Medicine Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1011 Horton Road, Albertville, AL 35950 Phone: 256-677-1475 | |
First Choice Family Medicine Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 431a N Carlisle St, Albertville, AL 35950 Phone: 256-601-1654 | |
Albertville Family Medicine Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 201 W Main St, Albertville, AL 35950 Phone: 256-929-9074 | |
William Alexander Nixon Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 11491 Us Highway 431, Albertville, AL 35950 Phone: 256-505-6826 Fax: 256-582-1100 | |
Medical Asset Group, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3442 Us Highway 431, Albertville, AL 35950 Phone: 256-907-9000 Fax: 256-907-9003 | |
John Christopher Brewer Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 11491 Us Highway 431, Ste. D, Albertville, AL 35950 Phone: 256-891-5102 Fax: 256-891-5103 |